Jeffrey M. Leiden - 02 May 2023 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Signature
/s/ Christiana Stevenson, Attorney-in-Fact
Issuer symbol
VRTX
Transactions as of
02 May 2023
Net transactions value
-$3,835,062
Form type
4
Filing time
04 May 2023, 16:50:03 UTC
Previous filing
28 Feb 2023
Next filing
09 May 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Sale $1,623,335 -4,645 -9.6% $349.48 43,704 02 May 2023 Direct F1, F2, F3
transaction VRTX Common Stock Sale $527,472 -1,505 -3.4% $350.48 42,199 02 May 2023 Direct F1, F2, F4
transaction VRTX Common Stock Sale $105,954 -300 -0.71% $353.18 41,899 02 May 2023 Direct F1, F2, F5
transaction VRTX Common Stock Sale $701,234 -2,008 -4.8% $349.22 39,891 03 May 2023 Direct F1, F2, F6
transaction VRTX Common Stock Sale $630,954 -1,800 -4.5% $350.53 38,091 03 May 2023 Direct F1, F2, F7
transaction VRTX Common Stock Sale $246,113 -700 -1.8% $351.59 37,391 03 May 2023 Direct F1, F2, F8
holding VRTX Common Stock 440 02 May 2023 401(k)
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1, which was entered into on 11/01/2022.
F2 Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F3 Open market sales reported on this line occurred at a weighted average price of $349.48 (range $349.00 to $349.99).
F4 Open market sales reported on this line occurred at a weighted average price of $350.48 (range $350.08 to $351.01).
F5 Open market sales reported on this line occurred at a weighted average price of $353.18 (range $352.63 to $353.53).
F6 Open market sales reported on this line occurred at a weighted average price of $349.22 (range $349.00 to $349.94).
F7 Open market sales reported on this line occurred at a weighted average price of $350.53 (range $350.08 to $350.90).
F8 Open market sales reported on this line occurred at a weighted average price of $351.59 (range $351.33 to $352.02).